GlassScriptPhysician profile
Amir M Khan
NPI 1467680868
$15,702.59
in general payments reported to CMS, 2019-2025
41 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $1,052 · 2021: $1,451 · 2022: $1,628 · 2023: $8,228 · 2024: $901 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,089 · Food and Beverage: $3,315 · Gift: $487 · Travel and Lodging: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,088.82 |
| Food and Beverage | $3,314.66 |
| Gift | $487.00 |
| Travel and Lodging | $345.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,832.23 | 2023 | Da Vinci Surgical System, Ion |
| Glaxosmithkline, LLC. | $1,470.52 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,217.29 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,138.81 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Mylan Specialty L.P. | $770.33 | 2019-2024 | Yupelri |
| Insmed, INC. | $765.57 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $526.71 | 2019-2024 | Dupixent |
| Pinnacle Biologics, INC | $300.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $288.01 | 2019 | |
| Genzyme Corporation | $277.34 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $271.27 | 2019-2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $184.37 | 2021-2025 | |
| United Therapeutics Corporation | $175.65 | 2020-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Hospital Products INC. | $143.91 | 2024-2025 | Acthar |
| Sanofi-Aventis U.S. LLC | $139.12 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $138.01 | 2021-2024 | Wakix |
| Philips North America LLC | $106.22 | 2019-2022 | |
| Verona Pharma, INC. | $102.89 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $98.62 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.96 | 2021-2022 | |
| Electromed, INC. | $81.58 | 2021-2025 | Smartvest |
| Grifols USA, LLC | $69.93 | 2023-2024 | Prolastin-C Liquid |
| Amgen INC. | $64.85 | 2021-2022 | |
| Tactile Systems Technology INC | $63.51 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Gilead Sciences, INC. | $57.52 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.12 | 2020-2023 | Glassia |
| Inogen, INC. | $39.64 | 2020-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Optinose US, INC. | $29.98 | 2024 | |
| Baxter Healthcare | $25.46 | 2023 | Hillrom - Life 2000 Ventilation System |
| Paratek Pharmaceuticals, INC. | $24.91 | 2024 | Nuzyra |
| Mallinckrodt Enterprises LLC | $19.31 | 2019 | |
| Circassia INC. | $18.02 | 2019 | |
| Lilly USA, LLC | $17.48 | 2025 | Zepbound |
| Pfizer INC. | $16.26 | 2020 | |
| Itamar Medical INC | $15.19 | 2021 | |
| Nabriva Therapeutics, Plc | $15.04 | 2021 | |
| Olympus America INC. | $14.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2023 | Camzyos |
| Pulmonx Corporation | $14.33 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Genentech USA, INC. | $11.22 | 2021 | |
| Veran Medical Technologies, INC. | $4.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.